You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 18, 2025

Acerus Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Acerus
International Patents:71
US Patents:4
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Acerus

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 DISCN Yes No 9,539,302 ⤷  Try for Free Y ⤷  Try for Free
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No 12,090,190 ⤷  Try for Free Y ⤷  Try for Free
Acerus NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 RX Yes Yes 11,090,312 ⤷  Try for Free ⤷  Try for Free
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 DISCN Yes No 12,090,190 ⤷  Try for Free Y ⤷  Try for Free
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 DISCN Yes No 11,419,914 ⤷  Try for Free ⤷  Try for Free
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No 9,539,302 ⤷  Try for Free Y ⤷  Try for Free
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No 11,419,914 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Acerus

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Acerus NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 8,877,230 ⤷  Try for Free
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 7,579,321 ⤷  Try for Free
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 7,579,321 ⤷  Try for Free
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 7,799,761 ⤷  Try for Free
Acerus NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 8,574,622 ⤷  Try for Free
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 7,405,203 ⤷  Try for Free
Acerus NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 8,784,882 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Acerus Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3225249 300983 Netherlands ⤷  Try for Free PRODUCT NAME: DESMOPRESSIN, DESGEWENST IN DE VORM VAN EEN ACETAAT ZOUT; REGISTRATION NO/DATE: BE497271 & BE497280 20160513
2712622 122017000006 Germany ⤷  Try for Free PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504
2712622 C02712622/01 Switzerland ⤷  Try for Free PRODUCT NAME: DESMOPRESSIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66379 16.03.2018
3225249 2019C/520 Belgium ⤷  Try for Free PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513
3225249 CA 2019 00023 Denmark ⤷  Try for Free PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504
2712622 LUC00015 Luxembourg ⤷  Try for Free PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Acerus – Market Position, Strengths & Strategic Insights

In the ever-evolving world of pharmaceuticals, understanding a company's position in the competitive landscape is crucial for success. Acerus Pharmaceuticals Corporation, a Canadian-based specialty pharmaceutical company, has carved out a niche for itself in the men's health sector. This article delves into Acerus' market position, strengths, and strategic insights, providing a comprehensive analysis of its competitive landscape.

Acerus Pharmaceuticals: An Overview

Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products. With a primary focus on men's health, Acerus has positioned itself as a key player in this niche market.

Core Product: Natesto®

At the heart of Acerus' product portfolio is Natesto®, a nasal gel formulation of testosterone. This innovative product has become the cornerstone of Acerus' market strategy and a significant driver of its growth.

"Natesto® is now the fastest-growing branded testosterone therapy in the market, which comes as no surprise to us." - Edward Gudaitis, President and Chief Executive Officer of Acerus Pharmaceuticals[10]

Market Position and Growth Strategy

Acerus has been making significant strides in establishing a strong market position, particularly in the United States. The company's growth strategy revolves around expanding its presence in the testosterone replacement therapy market.

U.S. Market Expansion

Acerus has been aggressively targeting the U.S. market, which represents a substantial opportunity for growth. The company estimates that approximately 14 million men in the U.S. may have hypogonadism, representing a $1 billion USD prescription market[6].

Sales and Marketing Efforts

To capitalize on this opportunity, Acerus launched a specialist-focused sales team in July 2020[6]. This strategic move has already shown promising results, with Natesto® prescriptions in the U.S. climbing 47% year-over-year in the second quarter of 2022[10].

Competitive Advantages

Acerus has several competitive advantages that set it apart in the pharmaceutical landscape:

1. Innovative Product Portfolio

Natesto®, Acerus' flagship product, offers unique benefits that differentiate it from other testosterone replacement therapies. Its nasal gel formulation provides effective symptom relief with 90% of men reaching normal testosterone levels[6].

2. Strong Safety Profile

Natesto® boasts a strong safety profile with low adverse events, making it an attractive option for patients and healthcare providers alike[6].

3. Unique Sperm Parameters

Unlike some other testosterone therapies, Natesto® maintains sperm parameters within the normal range, a significant advantage for men concerned about fertility[6].

4. Strategic Partnerships

Acerus has formed strategic partnerships to enhance its market reach. For instance, the company signed an agreement with Verity Pharmaceuticals for the exclusive rights to promote Natesto® in Puerto Rico[5].

Technological Edge: TransCon Technology

While not explicitly mentioned for Acerus, the use of innovative drug delivery technologies is a common competitive advantage in the pharmaceutical industry. Companies like Ascendis Pharma, for example, leverage proprietary technologies like the TransCon platform to develop novel therapies with improved efficacy, safety, and convenience[4].

Market Challenges and Opportunities

Despite its strengths, Acerus faces several challenges in the competitive pharmaceutical landscape:

Financial Challenges

Acerus has faced financial difficulties, as indicated by its low Financial Strength Rank of 1 on GuruFocus[7]. This suggests that the company may be in financial distress, which could impact its ability to compete effectively.

Regulatory Hurdles

Like all pharmaceutical companies, Acerus must navigate complex regulatory environments. Staying informed about regulatory requirements and compliance standards is crucial for the successful launch of pipeline products[4].

Opportunities for Growth

Despite these challenges, Acerus has several opportunities for growth:

  1. Expanding its product pipeline
  2. Entering new international markets
  3. Leveraging digital health technologies
  4. Exploring personalized medicine approaches

Strategic Moves and Future Outlook

Acerus is taking several strategic steps to strengthen its market position and drive future growth:

1. Acquisition of Serenity Pharmaceuticals

Acerus recently announced the acquisition of Serenity Pharmaceuticals, a move that is expected to accelerate top-line growth and improve long-term financial performance[2].

2. Relaunch of Noctiva™

The company is planning to relaunch Noctiva™, a treatment for nocturia, in the first quarter of 2023. This move is expected to complement Acerus' existing portfolio and leverage its established sales network[10].

3. Continued Focus on Natesto®

Acerus continues to prioritize the growth of Natesto®, aiming for mid double-digit market share and over $100 million USD in net revenue[6].

4. Exploration of New Technologies

While not explicitly stated for Acerus, staying abreast of biotechnology advancements and exploring new drug delivery technologies could be crucial for future competitiveness[4].

Competitive Landscape Analysis

To fully understand Acerus' position, it's important to consider the broader competitive landscape:

Major Competitors

While specific competitors are not mentioned in the provided sources, it's likely that Acerus competes with other pharmaceutical companies focused on men's health and hormone therapies.

Industry Trends

Several trends are shaping the pharmaceutical industry:

  1. Biotechnology advancements
  2. Shift towards personalized medicine
  3. Integration of digital health technologies
  4. Expanding global markets

Acerus will need to navigate these trends to maintain and improve its competitive position.

Key Takeaways

  • Acerus Pharmaceuticals has established a strong position in the men's health sector, particularly with its innovative product Natesto®.
  • The company is focusing on expanding its presence in the U.S. market, which represents a significant growth opportunity.
  • Acerus' competitive advantages include its innovative product portfolio, strong safety profile, and strategic partnerships.
  • Financial challenges and regulatory hurdles present ongoing challenges for the company.
  • Strategic moves, including the acquisition of Serenity Pharmaceuticals and the planned relaunch of Noctiva™, indicate a proactive approach to growth.
  • Staying abreast of industry trends and continuing to innovate will be crucial for Acerus' future success in the competitive pharmaceutical landscape.

FAQs

  1. What is Acerus Pharmaceuticals' main product? Acerus' main product is Natesto®, a nasal gel formulation of testosterone for treating hypogonadism.

  2. How is Acerus expanding its market presence? Acerus is focusing on the U.S. market, launching a specialist-focused sales team and forming strategic partnerships to promote its products.

  3. What are the main challenges facing Acerus? Key challenges include financial difficulties, regulatory hurdles, and competition in the pharmaceutical industry.

  4. What recent strategic moves has Acerus made? Acerus recently acquired Serenity Pharmaceuticals and is planning to relaunch Noctiva™, a treatment for nocturia.

  5. What are the future growth opportunities for Acerus? Future growth opportunities include expanding its product pipeline, entering new international markets, leveraging digital health technologies, and exploring personalized medicine approaches.

Sources cited: [2] https://www.globenewswire.com/news-release/2022/03/15/2403288/0/en/Acerus-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html [4] https://canvasbusinessmodel.com/blogs/competitors/ascendis-pharma-competitive-landscape [5] https://veritypharma.com/us/news-center/verity-pharmaceuticals-and-acerus-pharmaceuticals-form-commercial-agreement-for-the-promotion-of-natesto-in-puerto-rico?language_content_entity=en [6] http://s2.q4cdn.com/417379002/files/doc_presentations/2020/Acerus-Corporate-Deck_Nov2020_v17_public-deck.pdf [7] https://www.gurufocus.com/term/rank-balancesheet/FRA:3TP0 [10] https://www.biospace.com/acerus-reports-second-quarter-2022-financial-results

Last updated: 2025-02-12

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.